Evolus, Inc.
Develops and markets aesthetic medical products
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Evolus' stock, with a target price of $23, indicating significant growth potential.
Financial Health
Evolus is performing well in revenue and profit margins, showing strong cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EOLS
Self-Care & Confidence
Invest in the companies behind the powerful daily rituals that millions can't live without. These carefully selected beauty and skincare stocks blend established global leaders with innovative disruptors, all benefiting from famously loyal customers who drive consistent, recurring revenue.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Elective Market Growth
Rising demand for non‑surgical cosmetic procedures supports long‑term market potential, though revenues can ebb with consumer confidence.
Commercial Execution
Physician adoption and targeted marketing are key near‑term levers; execution risk matters for small, growth‑oriented firms.
International Opportunity
Selective global expansion via partners could broaden reach, but regulatory and distribution challenges add uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
